Cargando…

149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial

BACKGROUND: Patients with hematologic malignancies treated with anticancer immunosuppressive therapies (ITs) are at increased risk of herpes zoster (HZ). In a previous report of this phase 3, observer-blind, multicenter trial (NCT01767467), the adjuvanted recombinant zoster vaccine (RZV) was shown t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dagnew, Alemnew F, Ilhan, Osman, Lee, Won-Sik, Woszczyk, Dariusz, Kwak, Jae-Yong, Bowcock, Stella, Sohn, Sang Kyun, Rodriguez Macías, Gabriela, Chiou, Tzeon-Jye, Quiel, Dimas, Aoun, Mickael, Matilla, Maria Belen Navarro, De La Serna, Javier, Milliken, Samuel, Murphy, John, McNeil, Shelly A, Salaun, Bruno, Paolo, Emmanuel Di, Campora, Laura, López-Fauqued, Marta, El Idrissi, Mohamed, Schuind, Anne, Heineman, Thomas C, Van Den Steen, Peter, Oostvogels, Lidia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252456/ http://dx.doi.org/10.1093/ofid/ofy209.019

Ejemplares similares

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
por: Dagnew, Alemnew F., et al.
Publicado: (2021)

37. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine (RZV) in Immunocompromised Populations: an Overview of 6 Trials
por: Fauqued, Marta Lopez, et al.
Publicado: (2020)

Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials
por: López-Fauqued, Marta, et al.
Publicado: (2021)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial
por: Vink, Peter, et al.
Publicado: (2019)

1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial
por: Mrkvan, Tomas, et al.
Publicado: (2018)

Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

2482. Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients
por: Curran, Desmond, et al.
Publicado: (2018)

Results of a Safety Pooled Analysis of an Adjuvanted Herpes Zoster Subunit Vaccine in More than 14,500 Participants Aged 50 Years or Older
por: López-Fauqued, Marta, et al.
Publicado: (2017)

β(2)-Glycoprotein I Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis by Suppressing the Phosphorylation of Extracellular Signal-Regulated Kinase 1/2, Akt, and Endothelial Nitric Oxide Synthase
por: Chiu, Wen-Chin, et al.
Publicado: (2016)

Decay chain $^{149}_{64}$Gd --> $^{149}_{63}$Eu --> $^{149}_{62}$Sm
por: Cabrera, J A, et al.
Publicado: (1991)

MicroRNA-138 Suppresses Neutrophil Gelatinase-Associated Lipocalin Expression and Inhibits Tumorigenicity
por: Lee, Ying Chu, et al.
Publicado: (2012)

Study of $^{149}_{64}$Gd --> $^{149}_{63}$Eu --> $^{149}_{62}$Sm decay chain
por: Cabrera, J A, et al.
Publicado: (1992)

2483. Twelve-Month Immunogenicity and Safety of an Adjuvanted Recombinant Zoster Vaccine in Immunosuppressed Adults Post Renal Transplant: a Phase III Randomized Clinical Trial
por: Vink, Peter, et al.
Publicado: (2018)

Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial
por: Vink, Peter, et al.
Publicado: (2020)

Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
por: Stadtmauer, Edward A., et al.
Publicado: (2021)

7. Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?
por: Kim, Joon Hyung, et al.
Publicado: (2020)

5. How Does Frailty Impact the Efficacy, Reactogenicity, Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine? A Secondary Analysis of the ZOE-50 and ZOE-70 Studies
por: Andrew, Melissa K, et al.
Publicado: (2020)

Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials
por: Kim, Joon Hyung, et al.
Publicado: (2023)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: A Phase III, Group-Matched, Clinical Trial
por: Grupping, Katrijn, et al.
Publicado: (2017)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
por: Schwarz, Tino F, et al.
Publicado: (2017)

Unusual scalp crusted scabies in an adult T-cell leukemia/lymphoma patient
por: Lai, Yi-Chun, et al.
Publicado: (2011)

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine
por: Grupping, Katrijn, et al.
Publicado: (2017)

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
por: Curran, Desmond, et al.
Publicado: (2019)

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
por: Oostvogels, Lidia, et al.
Publicado: (2019)

Emission channeling experiments from the decay of $^{149}$Gd to $^{149}$Eu in GaN
por: De Vries, B, et al.
Publicado: (2003)

Diagnostic evaluation and assessment of anemia in a patient with chronic kidney disease and gastrointestinal angioectasias undergoing hemodialysis
por: Courville, Karen, et al.
Publicado: (2022)

149th SPSC Meeting
Publicado: (2023)

149th LHCC Meeting
Publicado: (2022)

A Developed NK-92MI Cell Line with Siglec-7(neg) Phenotype Exhibits High and Sustainable Cytotoxicity against Leukemia Cells
por: Huang, Chin-Han, et al.
Publicado: (2018)

Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
por: Curran, Desmond, et al.
Publicado: (2020)

Terbium-149 for targeted alpha therapy
por: Grundler, Pascal, et al.
Publicado: (2023)

Minutes of the 149th Meeting of the LHCC
por: CERN. Geneva. Large Hadron Collider Experiments Committee, et al.
Publicado: (2022)

Terbium-149 for targeted alpha therapy
por: Borgna, Francesca, et al.
Publicado: (2021)

Health Tract, No. 149: Diphtherial Disease
Publicado: (1863)

Health Tract, No. 149: Diphtherial Disease
Publicado: (1865)

Functional Analysis of the Ser149/Thr149 Variants of Human Aspartylglucosaminidase and Optimization of the Coding Sequence for Protein Production
por: Banning, Antje, et al.
Publicado: (2017)

Evaluation of the antibacterial effects and mechanism of Plantaricin 149 from Lactobacillus plantarum NRIC 149 on the peri-implantitis pathogens
por: Lin, Xiaolong, et al.
Publicado: (2021)

IAU Colloquium 149 : the Stellar Populations of Galaxies
por: Barbuy, B, et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_hu5eafdequ26h9k1di5om7k4ld